Drs. Ohar and Kalhan discuss the RETHINC trial results, which examined bronchodilators for symptomatic tobacco-exposed persons with preserved lung function. They share their insights on how this may impact the way current or former smokers with clinically significant respiratory symptoms will be treated in the future.
view more